Gang Xie

发表

Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics

B. Rigas, G. Mattheolabakis, Liqun Huang, 2013, International journal of oncology.

The novel phospho‐non‐steroidal anti‐inflammatory drugs, OXT‐328, MDC‐22 and MDC‐917, inhibit adjuvant‐induced arthritis in rats

B. Rigas, N. Ouyang, L. Huang, 2011, British journal of pharmacology.

Regioselective oxidation of phospho‐NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety

B. Rigas, P. Constantinides, Liqun Huang, 2012, British journal of pharmacology.

Phospho-Ibuprofen (MDC-917) Is a Novel Agent against Colon Cancer: Efficacy, Metabolism, and Pharmacokinetics in Mouse Models

L. Kopelovich, B. Rigas, Liqun Huang, 2011, Journal of Pharmacology and Experimental Therapeutics.

Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans.

B. Rigas, C. Wong, Ka-Wing Cheng, 2013, Biochemical pharmacology.

A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice.

B. Rigas, N. Ouyang, G. Mackenzie, 2013, Neoplasia.

Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.

B. Rigas, N. Ouyang, Liqun Huang, 2011, Cancer research.

Phospho-Sulindac (OXT-328) Combined with Difluoromethylornithine Prevents Colon Cancer in Mice

L. Kopelovich, B. Rigas, N. Ouyang, 2011, Cancer Prevention Research.

Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.

L. Kopelovich, B. Rigas, F. Johnson, 2010, Gastroenterology.

Phosphosulindac is efficacious in an improved concanavalin A‐based rabbit model of chronic dry eye disease

R. Honkanen, B. Rigas, Liqun Huang, 2018, Translational research : the journal of laboratory and clinical medicine.

Phospho-NSAIDs Have Enhanced Efficacy in Mice Lacking Plasma Carboxylesterase: Implications for their Clinical Pharmacology

B. Rigas, N. Ouyang, G. Mattheolabakis, 2014, Pharmaceutical Research.

The in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agent.

B. Rigas, Liqun Huang, Ka-Wing Cheng, 2014, Biochemical pharmacology.

Aerosol Administration of Phospho-Sulindac Inhibits Lung Tumorigenesis

B. Rigas, N. Ouyang, T. Wiedmann, 2013, Molecular Cancer Therapeutics.

Phospho-Sulindac (OXT-328) Inhibits the Growth of Human Lung Cancer Xenografts in Mice: Enhanced Efficacy and Mitochondria Targeting by its Formulation in Solid Lipid Nanoparticles

B. Rigas, P. Constantinides, Liqun Huang, 2012, Pharmaceutical Research.

The metabolism and pharmacokinetics of phospho‐sulindac (OXT‐328) and the effect of difluoromethylornithine

L. Kopelovich, B. Rigas, P. Constantinides, 2012, British journal of pharmacology.

Carboxylesterases 1 and 2 Hydrolyze Phospho-Nonsteroidal Anti-Inflammatory Drugs: Relevance to Their Pharmacological Activity

B. Rigas, P. Constantinides, C. Wong, 2012, Journal of Pharmacology and Experimental Therapeutics.

Therapeutics , Targets , and Chemical Biology ChemotherapeuticPropertiesofPhospho-Nonsteroidal Anti-In fl ammatory Drugs , a New Class of Anticancer Compounds

B. Rigas, N. Ouyang, Liqun Huang, 2011 .

6′-O-Galloylpaeoniflorin Attenuates Osteoclasto-genesis and Relieves Ovariectomy-Induced Osteoporosis by Inhibiting Reactive Oxygen Species and MAPKs/c-Fos/NFATc1 Signaling Pathway

Heng-Bin Li, G. Yao, G. Yuan, 2021, Frontiers in Pharmacology.

In Vitro and In Vivo Metabolic Studies of Phospho-aspirin (MDC-22)

B. Rigas, P. Constantinides, Liqun Huang, 2012, Pharmaceutical Research.